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In 1945, Drs Bernhard Zondek and Yehuda
Bromberg demonstrated intradermal treatment with
estrone and estradiol benzoate induced urticarial
lesions in some patients.1 Fifty years later, Shelley
et al,2 who introduced the concept of progesterone
dermatitis several decades prior, defined estrogen
dermatitis based on studies of 7 women with pre-
menstrual flares of skin eruptions including papulo-
vesicular, urticarial, or eczematous lesions or
generalized pruritus. Previously described therapies
for estrogen dermatitis include estrogen desensitiza-
tion, tamoxifen, leuprolide, and oophorectomy.3
Here we report a case of estrogen-induced dermatitis
successfully treated with omalizumab.
CASE REPORT
We previously described the case of a 37-year-old
woman who presented with a longstanding history
([10 years) of a waxing and waning polymorphous
eruption consisting of symmetrically distributed
migratory pruritic and occasionally painful arcuate
erythematous plaques involving themedial aspects of
thebreasts consistentwith a gyrate erythema (Fig 1) as
well as urticarial plaques scattered on the trunk and
extremities.3 Flares regularly began on or near day 2
of menses, and lasted for approximately 2 weeks.3
Intradermal injections (0.1 mL) of conjugated estro-
gen (100 g), medroxyprogesterone (100 g), hista-
mine, and normal saline were administered to the
patient’s forearm.3 Estrogen and histamine injectionDepartments of Dermatologyb and Medicine,c Indiana
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ity School of Medicine, Department of Dermatology,sites were positive for wheal formation within 15 mi-
nutes, but no reactionwas seen in the progesteroneor
saline injection sites.3 Based on the clinical presenta-
tion and skin testing, estrogen dermatitis was diag-
nosed. This condition did not respond to an oral
antihistamine regimenof 10mg cetirizine daily and 10
to 20 mg of hydroxyzine nightly. Although significant
improvement was seen with a 6-month course of
leuprolide, (11.25-mg injections every 3 months), the
response was incomplete, and leuprolide was subse-
quently discontinuedwhen the patient underwent an
elective hysterectomy andbilateral oophorectomy for
symptomatic uterine fibroids.3 Despite this surgery,
the patient’s estrogen dermatitis persisted. Given lack
of or insufficient control provided by the therapies
mentionedabove, thepatient, at 41 years of age (body
mass index, 34 kg/m2), elected to begin treatment
with omalizumab, 150 mg subcutaneously every
4 weeks. Treatment with omalizumab rapidly cleared
the patient’s estrogen dermatitis, which has nowbeen
well controlled with monthly omalizumab infusions
for 2 years. In asthma, use and dosing of omalizumab
are determined by body weight and total serum IgE;
however, total serum IgE and body weight are not
used to guide use or dosing of omalizumab
for chronic idiopathic urticaria, for which dosing
options are 150 mg or 300 mg every 4 weeks. Based
on this finding, baseline IgE measurements were
not obtained in our patients, and the lower dose
(150 mg) was chosen with the plan to increase if
needed.45 Barnhill Dr EH139, Indianapolis, IN 46202. E-mail: turner41@
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Fig 1. Estrogen dermatitis manifesting as arcuate erythem-




482 Ocana et alDISCUSSION
The pathophysiology of estrogen-induced urti-
carial eruptions and dermatitis remains to be
defined. In addition to demonstrating that intrader-
mal estrogen administration could induce urticarial
eruptions in patients, Zondek and Bromberg1 re-
ported that serum from estrogen-sensitive patients
could induce similar skin reaction in na€ıve patients.
These investigators also found that heating serum
from estrogen-sensitive patients to 568C prior to
passive transfer reduced the severity of these urti-
carial eruptions, leading the investigators to suggest
these eruptions were antibody dependent.3 The
cyclical course of our patient’s skin eruption in
relation to menses, coupled with positive intrader-
mal testing to estrogen and the urticarial component
to the eruption led us to hypothesize her estrogen
dermatitis might represent a type of IgE-mediated
hypersensitivity reaction, which was the basis for a
therapeutic trial of omalizumab.
Omalizumab is a neutralizing IgG monoclonal
antibody that binds free circulating IgE. This binding
inhibits IgE from binding its high-affinity Fc receptor
on the surface of mast cells and basophils. Currently,
omalizumab is approved for the treatment of chronic
idiopathic urticaria and asthma with some efficacy
extending into other IgE-mediated diseases.4 The
fact that the patient’s cutaneous manifestations
improved after treatment with omalizumab suggests
that this condition is mediated by a hypersensitivity
reaction involving IgE. From the standpoint of a type
I hypersensitivity reaction, the insufficiency of anti-
histamines to control our patient’s skin eruption
suggests other mediators could be involved in the
pathogenesis of estrogen dermatitis. Preformed mast
cellederived mediators that could also contribute
include granule-stored polyamines, proteoglycans,
proteases, lysosomal enzymes, and cytokines.5Additionally, activation of the Fc receptor could
stimulate mast cell de novo synthesis and release of
other mediators including cytokines, prostaglandins,
and reactive oxygen species. Although classically
implicated in type I hypersensitivity reactions, IgE
can also alter T-cell function through engagement of
the high-affinity IgE receptor on dendritic cells
suggesting a potential for IgE to contribute to type
IV hypersensitivity reactions in some settings.6 The
ability of IgE to contribute to different types of
hypersensitivity reactions (ie, immediate and de-
layed types) could explain the polymorphous nature
of this patient’s estrogen dermatitis (ie, gyrate ery-
thema and urticaria).
Another notable aspect of this case was that the
patient’s estrogen dermatitis was refractory to oopho-
rectomy. The persistence of the patient’s estrogen
dermatitis was surprising (as the ovaries are the
primary producers of estrogen) and prompted us to
consider other potential sources of this hormone.2
Our patient’s body mass index was 34 kg/m2;
considering the association of increased estrogen
levels with greater adiposity, it is possible that
her estrogen dermatitis persisted because of periph-
eral aromatases in the fat converting adrenal
glandederived androgens into estradiol.7 If this is
the case, reducing adiposity through weight reduc-
tion would also be a therapeutic consideration to
manage estrogen dermatitis. Other possible sources
of estrogens to consider in this case would include
residual ovarian tissue present after oophorectomy or
dietary or environmental exposures. Phytoestrogens,
naturally present in soy and grains, and phthalates,
commonly found in plastics associated with food
storage and household items, are structurally similar
to endogenous estrogen.8
We present a case of estrogen dermatitis respon-
sive to omalizumab. The unique treatment approach
and favorable response for this patient may shed
light on the pathophysiology of this condition. More
specifically, this case supports a role for IgE in
pathogenesis and suggests that omalizumab should
be considered in the therapeutic ladder for estrogen
dermatitis.
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